Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Survival for the major cancer killers in the US
- Epigenetics versus genetics
- Methylation of cytosine
- Structure of the known DNA methyltransferases
- Histone modifications in promoters during cancer
- Cytosine methylation and chromatin remodeling
- Gene specific promoter hypermethylation
- Biological fluids and cancer detection
- Methylation specific PCR
- Methylation specific PCR assay
- Two step methylation specific PCR
- Real time assay for detecting methylation
- Challenges for methylation-based assays
- Lung cancer
- p16 methylation during carcinoma development
- Gene promoter methylation as a biomarker
- Previous studies continued
- Strategy for early detection of lung cancer
- Goal (1)
- Colorado cohort study of smokers with COPD
- Colorado nested, case control sputum study
- Candidate methylation biomarkers evaluated
- Prevalence for gene methylation in sputum (1)
- Sputum evaluation and cancer diagnosis
- Key question
- Prevalence for gene methylation in sputum (2)
- Gene panel methylation in cancer detection (1)
- Conclusions and future strategy
- Gene promoter methylation in plasma
- Goal (2)
- Summary of selected variables
- Prevalence for gene methylation in plasma (1)
- Prevalence for gene methylation in plasma (2)
- Prevalence for gene methylation in sputum
- Gene panel methylation in cancer detection (2)
- Conclusions (1)
- Gene promoter methylation: utility for diagnosis
- Methylation of p16 and H-cadherin
- Emerging applications
- Colon cancer detection in stool
- Bladder cancer detection in urine
- Prostate cancer diagnosis and staging
- Prostate cancer detection in urine
- Conclusions (2)
- Thank you
Topics Covered
- How genes are silenced epigenetically via cytosine methylation and chromatin remodeling
- Assays for detecting gene promoter methylation in biological fluids
- Challenges for developing methylation-based assays
- Lung cancer case-control study of gene promoter methylation in sputum
- Predicting risk for lung cancer through gene methylation detection in plasma
- Gene promoter methylation as a diagnostic tool for lung, colon, prostate, and bladder cancer
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Belinsky, S. (2010, July 1). DNA methylation as a tumor marker: implications for diagnosis, early detection and risk assessment [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/BWWX7303.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Steve Belinsky has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
DNA methylation as a tumor marker: implications for diagnosis, early detection and risk assessment
Published on July 1, 2010
41 min
A selection of talks on Cancer
Hide